SCHEMBL6095280

SCHEMBL6095280

COc1ccc(C(=O)Nc2cc(O)ccc2C(=O)O)cc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.63
PIM1 P11309 1/20 0.63
MAPK8 P45983 1/20 0.63
CLK4 Q9HAZ1 1/20 0.63
TDP1 Q9NUW8 3/20 0.62
ABL1 P00519 1/20 0.62
RIN1 Q13671 1/20 0.62
AKR1C4 P17516 1/20 0.60
AKR1C3 P42330 1/20 0.60
AKR1C2 P52895 1/20 0.60
AKR1C1 Q04828 1/20 0.60
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
ALDH1A1 P00352 4/20 0.59
RAB9A P51151 3/20 0.59
HTT P42858 2/20 0.59
NPC1 O15118 1/20 0.59
KCNH2 Q12809 1/20 0.59
MAPT P10636 3/20 0.57
PDE4D Q08499 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091049 0.91 TDP1 (0.74) CHEK1PIM1MAPK8CLK4TDP1
SCHEMBL6092606 0.90 CHEK1 (0.63) CHEK1PIM1MAPK8CLK4TDP1
SCHEMBL4670317 0.88 CHEK1 (0.81) CHEK1PIM1MAPK8CLK4TDP1
SCHEMBL9973845 0.84 TOP1 (0.59) TDP1ABL1RIN1AKR1C4AKR1C3
SCHEMBL14227331 0.83 MEN1 (0.67) CHEK1PIM1MAPK8CLK4TDP1
SCHEMBL6093998 0.81 TDP1 (0.74) CHEK1PIM1MAPK8CLK4TDP1
SCHEMBL4669087 0.80 MEN1 (0.65) TDP1ABL1RIN1AKR1C4AKR1C3
SCHEMBL14227330 0.80 KMT2A (0.67) CHEK1PIM1MAPK8CLK4TDP1
SCHEMBL9973843 0.79 TOP1 (0.58) TDP1ABL1RIN1KMT2AMEN1
SCHEMBL14290075 0.79 PDE4D (0.55) CHEK1PIM1MAPK8CLK4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L SYMRISE AG (DE) 2023-04-20 US disclosed
EP-1959915-B1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE AG (DE) 2015-05-13 EP disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 US disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS SYMRISE AG (DE) 2012-12-13 US disclosed
US-8203016-B2 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE AG (DE) 2012-06-19 US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 US disclosed
EP-1886662-A1 Anti-microbial compounds for treating bad breath Symrise GmbH & Co. KG (DE) 2008-02-13 EP disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 US disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 US disclosed
WO-2007062957-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2007-06-07 WO disclosed
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE GMBH & CO. KG (DE) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents HRH1, CMA1, HRH2 CHEK1 3732/4885PIM1 4368/4885MAPK8 2568/4885
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching H1-0, ASIC1, MCOLN1 CHEK1 1679/4885PIM1 4784/4885MAPK8 1741/4885
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE HPD, CYP4A22, PAH CHEK1 1692/4885PIM1 2137/4885MAPK8 3878/4885
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING H1-0, ASIC1, NHERF1 CHEK1 3976/4885PIM1 4120/4885MAPK8 2466/4885
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS CMA1, TPSAB1, HRH1 CHEK1 4081/4885PIM1 4410/4885MAPK8 2759/4885
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY OAT, PIGS, HLA-A CHEK1 2054/4885PIM1 3052/4885MAPK8 3088/4885
US-20080008660-A1 Antimicrobially active compounds for treating bad breath CAT, LPO, GPX1 CHEK1 4358/4885PIM1 1531/4885MAPK8 4280/4885
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L TACR1, NPSR1, TACR2 CHEK1 1243/4885PIM1 3737/4885MAPK8 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.